Katherine A Lyseng-Williamson

Summary

Affiliation: Adis International Limited
Country: New Zealand

Publications

  1. ncbi request reprint Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler
    Sohita Dhillon
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1475-83; discussion 1484-5. 2006
  2. doi request reprint Fesoterodine
    Kate McKeage
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    Drugs 69:731-8. 2009
  3. ncbi request reprint Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels
    Natalie J Carter
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 10:383-400. 2010
  4. ncbi request reprint Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU
    Lily P H Yang
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 72:229-48. 2012
  5. doi request reprint Quetiapine: a pharmacoeconomic review of its use in bipolar disorder
    Greg L Plosker
    Adis, Auckland, New Zealand
    Pharmacoeconomics 30:611-31. 2012
  6. ncbi request reprint Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus
    R H Foster
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 18:289-306. 2000
  7. ncbi request reprint Lansoprazole: an update of its place in the management of acid-related disorders
    A J Matheson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:1801-33. 2001
  8. ncbi request reprint Extended-release methylphenidate (Ritalin LA)
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2251-9; discussion 2260-1. 2002
  9. ncbi request reprint Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis
    John Waugh
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:55-64; discussion 65-6. 2004
  10. ncbi request reprint Spotlight on verteporfin in subfoveal choroidal neovascularisation
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:203-9. 2004

Collaborators

Detail Information

Publications1128 found, 100 shown here

  1. ncbi request reprint Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler
    Sohita Dhillon
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 66:1475-83; discussion 1484-5. 2006
    ..Moreover, a single high dose of BDP/formoterol (1000 microg/60 microg) was generally well tolerated in patients with asthma...
  2. doi request reprint Fesoterodine
    Kate McKeage
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    Drugs 69:731-8. 2009
    ..black triangle Fesoterodine 4 or 8 mg once daily was generally well tolerated in patients with OAB; the most frequent adverse event was dry mouth, which was generally mild to moderate in severity...
  3. ncbi request reprint Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels
    Natalie J Carter
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 10:383-400. 2010
    ....
  4. ncbi request reprint Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU
    Lily P H Yang
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 72:229-48. 2012
    ..In conclusion, saxagliptin is a useful option as add-on therapy to metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) in patients with type 2 diabetes who require combination therapy...
  5. doi request reprint Quetiapine: a pharmacoeconomic review of its use in bipolar disorder
    Greg L Plosker
    Adis, Auckland, New Zealand
    Pharmacoeconomics 30:611-31. 2012
    ....
  6. ncbi request reprint Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus
    R H Foster
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 18:289-306. 2000
    ....
  7. ncbi request reprint Lansoprazole: an update of its place in the management of acid-related disorders
    A J Matheson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:1801-33. 2001
    ..Lansoprazole has emerged as a useful and well tolerated treatment option in the management of acid-related disorders...
  8. ncbi request reprint Extended-release methylphenidate (Ritalin LA)
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2251-9; discussion 2260-1. 2002
    ..In clinical trials, the safety and tolerability profiles of extended-release methylphenidate were consistent with that of the immediate-release formulation...
  9. ncbi request reprint Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis
    John Waugh
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:55-64; discussion 65-6. 2004
    ..black triangle Ciprofloxacin XR was generally well tolerated in patients with uncomplicated or complicated UTIs or acute uncomplicated pyelonephritis and showed similar tolerability to that of the immediate-release formulation...
  10. ncbi request reprint Spotlight on verteporfin in subfoveal choroidal neovascularisation
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 21:203-9. 2004
    ..Approximately 5% of patients with occult with no classic subfoveal CNV secondary to AMD reported severe vision decrease within 7 days of treatment in clinical trials; 3 months later, several patients had recovered some of this loss...
  11. ncbi request reprint Sumatriptan fast-disintegrating/rapid-release tablets
    Marit D Moen
    Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:883-90. 2006
    ..Sumatriptan FDT/RRT tablets were generally well tolerated; the tolerability profile was similar to that reported for standard sumatriptan tablets in other studies...
  12. ncbi request reprint Trastuzumab: a pharmacoeconomic review of its use in early breast cancer
    Kate McKeage
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 26:699-719. 2008
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of adjuvant trastuzumab for 1 year as a cost-effective treatment relative to chemotherapy alone in this patient population...
  13. ncbi request reprint Caspofungin: in pediatric patients with fungal infections
    Karly P Garnock-Jones
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    Paediatr Drugs 11:259-69. 2009
    ..Few caspofungin recipients reported serious drug-related adverse events or discontinued treatment as a result of drug-related adverse events...
  14. ncbi request reprint Inhaled budesonide/formoterol combination
    J K McGavin
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:71-8; discussion 79-80. 2001
    ..No adverse effects on pulse rate, blood pressure or serum potassium have been reported with combination therapy...
  15. ncbi request reprint Rosuvastatin
    Christopher I Carswell
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2075-85; discussion 2086-7. 2002
    ..Rosuvastatin was well tolerated in clinical trials of up to 1 years' duration...
  16. ncbi request reprint Duloxetine: in stress urinary incontinence
    Paul L McCormack
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2567-73; discussion 2574-5. 2004
    ..Mean I-QOL total scores suggested that combination therapy was more effective than either therapy alone. Nausea was the most frequent adverse event and was the main cause for discontinuing duloxetine therapy...
  17. ncbi request reprint Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia
    Paul L McCormack
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2719-40. 2005
    ..Therefore, once-daily PR nicotinic acid appears to maximise the potential benefits of nicotinic acid, while minimising any historical tolerability or safety concerns...
  18. ncbi request reprint Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    BioDrugs 20:63-5. 2006
    ..Eptifibatide is well tolerated in these trials. Ongoing trials are currently investigating the efficacy and tolerability of regimens that include this agent in other indications, including ST-segment elevation MI...
  19. ncbi request reprint Ultra-short-course seasonal allergy vaccine (Pollinex Quattro)
    Paul L McCormack
    Adis International Limited, 51 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 66:931-8. 2006
    ..The allergy vaccine was generally well tolerated. Local reactions, mainly injection-site redness and swelling, were more common than systemic reactions. There were no serious adverse events...
  20. ncbi request reprint Recombinant full-length parathyroid hormone (1-84): profile report
    Marit D Moen
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 21:205-8. 2007
  21. ncbi request reprint Aripiprazole: in adolescents with schizophrenia
    Mark Sanford
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Paediatr Drugs 9:419-23. 2007
    ..The mean weight change was significantly different in aripiprazole and placebo recipients (0, +2, and -0.8 kg in aripiprazole 10 mg/day, aripiprazole 30 mg/day, and placebo recipients, respectively)...
  22. ncbi request reprint Olmesartan medoxomil: a review of its use in the management of hypertension
    Lesley J Scott
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1239-72. 2008
    ....
  23. ncbi request reprint Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection
    Caroline M Perry
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1189-213. 2010
    ..Available data indicate that maraviroc may also have a role in treatment-naive adults with CCR5-tropic HIV-1 infection, a population in whom CCR5-tropic HIV-1 is often the major quasispecies...
  24. doi request reprint Sitafloxacin: in bacterial infections
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:731-44. 2011
    ..Adverse reactions reported in sitafloxacin recipients in the active comparator trials were of mild to moderate severity...
  25. ncbi request reprint Fluvastatin: a review of its use in lipid disorders
    H D Langtry
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:583-606. 1999
    ..5 years (-0.028 vs -0.01 mm, p < 0.005). The Lescol in Symptomatic Angina study found reductions in all cardiac events or cardiac death in patients after 1 year of fluvastatin 40 mg/day (1.6% vs 5.6% for placebo, p < 0.05)...
  26. ncbi request reprint Desirudin: a review of its use in the management of thrombotic disorders
    A J Matheson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 60:679-700. 2000
    ..However, in the GUSTO IIb trial a significantly higher incidence of transfusions was observed in patients with unstable angina/non-Q-wave MI...
  27. ncbi request reprint Indobufen: an updated review of its use in the management of atherothrombosis
    N Bhana
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs Aging 18:369-88. 2001
    ..6 vs 5.1%) and major bleeding events occurred only in the warfarin group...
  28. ncbi request reprint Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension
    Ezequiel Balmori Melian
    Adis International Limited, Auckland, New Zealand
    Drugs 62:787-816. 2002
    ..4%), dizziness (2.6 vs 1.2%) and respiratory infection (2.5 vs 1.4%). Moreover, 3.3 and 2.7% of patients receiving candesartan cilexetil/hydrochlorothiazide or placebo, respectively, discontinued treatment because of adverse events...
  29. ncbi request reprint Delayed-release lansoprazole plus naproxen
    Monique P Curran
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1915-9; discussion 1920-1. 2004
    ....
  30. ncbi request reprint Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1975-96. 2004
    ..The DPI combining a corticosteroid and long-acting beta2-agonist provides benefits over monotherapy and may encourage patient compliance in COPD...
  31. ncbi request reprint Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 24:297-314. 2006
    ....
  32. ncbi request reprint Spotlight on topical pimecrolimus in pediatric atopic dermatitis
    Lily P H Yang
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Clin Dermatol 11:295-8. 2010
    ....
  33. doi request reprint Dapoxetine: in premature ejaculation
    Sheridan M Hoy
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:1433-43. 2010
    ....
  34. ncbi request reprint Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer
    James E Frampton
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 64:2475-92. 2004
    ..These findings have been supported by observations from a global compassionate-use programme. Ongoing or planned clinical trials are designed to confirm and/or further define the role of the drug in the above and other clinical settings...
  35. ncbi request reprint Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
    A Markham
    Adis International Limited, Auckland, New Zealand
    Drugs 54:299-311. 1997
    ..Thus, valsartan is an effective treatment for mild to moderate essential hypertension and may be particularly useful in patients who experience persistent cough during ACE inhibitor therapy...
  36. ncbi request reprint Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer
    Dene Simpson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:2127-56. 2003
    ..Withdrawals from oxaliplatin treatment were due to neuropathy (up to 10%), diarrhoea and/or vomiting (1%) or cutaneous toxicity (1%)...
  37. ncbi request reprint Spotlight on oxcarbazepine in epilepsy
    Lynne M Bang
    Adis International Ltd, Auckland, New Zealand
    CNS Drugs 18:57-61. 2004
    ..Nevertheless, the generally favorable tolerability profile and relatively low potential for drug interactions of oxcarbazepine make it a valuable option in the treatment of childhood epilepsy...
  38. ncbi request reprint Emtricitabine/tenofovir disoproxil fumarate
    Toni M Dando
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2075-82; discussion 2083-4. 2004
    ..Diarrhoea, nausea and vomiting were the most common adverse events reported with coadministered emtricitabine and tenofovir DF as separate formulations as part of combination therapy...
  39. ncbi request reprint Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention
    Marit D Moen
    Adis International Limited, Auckland, New Zealand
    Drugs 65:1869-91. 2005
    ..Bivalirudin should be considered as an alternative to heparin plus planned GP IIb/IIIa inhibition in any patient undergoing urgent or elective PCI, especially in any patient with a high risk of bleeding complications...
  40. ncbi request reprint Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A
    James E Frampton
    Wolters Kluwer Health Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 68:839-53. 2008
    ..Available data indicate that sucrose-formulated octocog alfa is an appropriate alternative to other recombinant FVIII products for the treatment and prophylaxis of bleeding episodes in adults and children with haemophilia A...
  41. ncbi request reprint Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer
    Claudine M Baldwin
    Adis, North Shore, Auckland, New Zealand
    Drugs 69:2279-302. 2009
    ..Pemetrexed is an important option for the management of NSCLC, in particular as targeted therapy in patients with non-squamous histology...
  42. ncbi request reprint Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction
    Jamie D Croxtall
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 25:243-54. 2011
    ....
  43. doi request reprint Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder
    R H Foster
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand
    CNS Drugs 8:163-88. 1997
    ..The individual incidences for these events ranged from 18 to 25%; however, the incidence of headache in paroxetine-treated patients was the same as that in placebo recipients. (ABSTRACT TRUNCATED)..
  44. ncbi request reprint Calfactant: a review of its use in neonatal respiratory distress syndrome
    S V Onrust
    Adis International Limited, Auckland, New Zealand
    Paediatr Drugs 1:219-43. 1999
    ..Acute adverse events were usually transient and not severe...
  45. ncbi request reprint Enoxaparin: an update of its clinical use in the management of acute coronary syndromes
    Tim Ibbotson
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1407-30. 2002
    ..In contrast, the rates of minor bleeding were higher in patients receiving enoxaparin than in those receiving UFH throughout these studies...
  46. ncbi request reprint Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1839-47. 2004
    ..The most frequently reported grade 3-4 adverse events with paclitaxel administered sequentially to AC were haematological events (neutropenia, thrombocytopenia, anaemia) and nausea/vomiting...
  47. ncbi request reprint Vildagliptin
    Sheridan Henness
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 66:1989-2001; discussion 2002-4. 2006
    ..Gastrointestinal adverse events were mild to moderate in intensity, and occurred less frequently than with metformin. Hypoglycaemic events were rare and occurred at a similar incidence to that with placebo...
  48. doi request reprint Duloxetine: a review of its use in the treatment of generalized anxiety disorder
    Natalie J Carter
    Wolters Kluwer Health mid R Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA
    CNS Drugs 23:523-41. 2009
    ..No deaths or suicides were reported in any of the short-term trials. Discontinuation-emergent adverse events, most commonly nausea and dizziness, occurred in up to one-third of duloxetine recipients in the short-term trials...
  49. doi request reprint Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer
    James E Frampton
    Adis, Auckland, New Zealand
    Drugs 69:2125-48. 2009
    ..Lapatinib combined with capecitabine provides an effective therapeutic option for a group of patients who currently have few treatment choices...
  50. ncbi request reprint Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain
    Sohita Dhillon
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Clin Drug Investig 30:711-38. 2010
    ....
  51. ncbi request reprint Indacaterol: in chronic obstructive pulmonary disease
    Marit D Moen
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:2269-80. 2010
    ..Indacaterol was generally well tolerated by adults with moderate to severe COPD...
  52. doi request reprint Nanofiltered human C1 inhibitor concentrate (Cinryze®): in hereditary angioedema
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 25:317-27. 2011
    ..Intravenous C1-INH NF concentrate was well tolerated in clinical trials in patients with HAE. No cases of viral transmission were reported...
  53. ncbi request reprint Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus
    C R Culy
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:1625-60. 2001
    ....
  54. ncbi request reprint Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder
    Marit D Moen
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 23:1057-83. 2009
    ....
  55. doi request reprint Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia
    Karly P Garnock-Jones
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 25:401-4. 2011
    ..Eltrombopag is an effective treatment option for adult patients with chronic ITP and an increased risk of bleeding who are refractory to previous treatments, including splenectomy, as demonstrated in well designed clinical trials...
  56. ncbi request reprint Nelfinavir
    C M Perry
    Adis International Limited, Auckland, New Zealand
    Drugs 54:81-7; discussion 88. 1997
    ..Plasma HIV RNA decreased to below detectable levels in 11 of 12 patients with early onset HIV infection who received a triple regimen of nelfinavir, zidovudine and lamivudine for 16 weeks...
  57. ncbi request reprint Etanercept: a review of its use in rheumatoid arthritis
    B Jarvis
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:945-66. 1999
    ..Injection site reactions occurred more frequently in etanercept- than placebo-treated patients, but did not bias the results of any study...
  58. ncbi request reprint Palivizumab
    L J Scott
    Adis International Limited, Auckland, New Zealand
    Drugs 58:305-11; discussion 312-3. 1999
    ..The incidence of adverse events was similar in placebo (10%) and palivizumab (11%) groups. Fever, irritability and injection site reaction were the most commonly reported adverse events...
  59. ncbi request reprint Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness
    S M Cheer
    Adis International Limited, Auckland, New Zealand
    Drugs 61:81-110. 2001
    ..Rates of sexual dysfunction and suicidal ideation with fluoxetine appear similar to those seen with other SSRIs...
  60. ncbi request reprint Sitagliptin
    Katherine A Lyseng-Williamson
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:587-97. 2007
    ..The incidence of hypoglycaemia with sitagliptin was similar to that with placebo and, in combination with metformin, lower than that with glipizide. Sitagliptin had a generally neutral effect on bodyweight...
  61. doi request reprint Bevacizumab: in previously treated glioblastoma
    Marit D Moen
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:181-9. 2010
    ..In the AVF3708g trial, grade 3 or higher treatment-emergent adverse events occurred in 46.4% of bevacizumab and 65.8% of bevacizumab plus irinotecan recipients...
  62. doi request reprint Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:89-99. 2011
    ..Ocular adverse events (e.g. eye pain, eye irritation) were the most commonly reported treatment-related adverse events, with the majority being of mild severity...
  63. doi request reprint Crizotinib: in locally advanced or metastatic non-small cell lung cancer
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 72:99-107. 2012
    ..Crizotinib was generally well tolerated, with most adverse reactions being grade 1 or 2. The most commonly reported treatment-related adverse reactions were vision disorder, gastrointestinal disorders and oedema...
  64. doi request reprint Levetiracetam
    M Haria
    Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand
    CNS Drugs 7:159-64. 1997
    ..These results require confirmation.[Symbol: see text] Somnolence and asthenia were the most common adverse events reported in patients receiving levetiracetam 1000 to 4000 mg/day; these appeared to be dose-related...
  65. ncbi request reprint Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders
    R Davis
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 10:299-322. 1997
    ..Thus, nadroparin should be considered an effective and well tolerated alternative to UFH for prophylaxis and treatment of DVT in older patients, with the advantage of more convenient administration and decreased monitoring requirements...
  66. ncbi request reprint Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders
    D C Peters
    Adis International Limited, Auckland, New Zealand
    Drugs 56:871-93. 1998
    ..Most adverse events are mild and transient in nature, and include cough, asthenia, dizziness, headache and nausea. Trandolapril has no adverse effect on lipid or carbohydrate metabolism...
  67. ncbi request reprint Telmisartan
    K J McClellan
    Adis International Limited, Auckland, New Zealand
    Drugs 56:1039-44; discussion 1045-6. 1998
    ..Telmisartan had a tolerability profile similar to that of placebo in clinical studies...
  68. ncbi request reprint Dexmedetomidine
    N Bhana
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 59:263-8; discussion 269-70. 2000
    ..Dexmedetomidine was well tolerated in phase III studies. The most frequently observed adverse events were hypotension, bradycardia and nausea...
  69. ncbi request reprint Moxifloxacin in uncomplicated skin and skin structure infections
    Richard B R Muijsers
    Adis International Limited, Auckland, New Zealand
    Drugs 62:967-73; discussion 974-5. 2002
    ..The most common adverse events reported during moxifloxacin treatment are gastrointestinal disturbances. The potential for photosensitivity reactions during moxifloxacin treatment is low...
  70. ncbi request reprint Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy
    Keri Wellington
    Adis International Limited, Auckland, New Zealand
    Drugs 63:417-37. 2003
    ..The most commonly reported adverse events included flu-like symptoms (fever, arthralgias, myalgias and bone pain), fatigue, gastrointestinal reactions, anaemia, weakness, dyspnoea and oedema...
  71. ncbi request reprint Escitalopram: a review of its use in the management of anxiety disorders
    Sohita Dhillon
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    CNS Drugs 20:763-90. 2006
    ..Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD...
  72. ncbi request reprint Fluticasone furoate: intranasal use in allergic rhinitis
    Paul L McCormack
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:1905-15. 2007
    ..Fluticasone furoate nasal spray was well tolerated in adults, adolescents and children aged 2-11 years, with an overall incidence of adverse events similar to that with placebo...
  73. doi request reprint Niacin extended-release/simvastatin
    Mark Sanford
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:2373-86. 2008
    ..Niacin ER/simvastatin was generally well tolerated, with flushing being the most common adverse reaction...
  74. ncbi request reprint Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension
    J A Balfour
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 10:384-403. 1997
    ..Further efficacy and tolerability data are needed to determine the place of dorzolamide in therapy...
  75. ncbi request reprint Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection
    D P Figgitt
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 60:481-516. 2000
    ..Compared with the HGC formulation, saquinavir SGC appears to be associated with a higher overall incidence of adverse events...
  76. ncbi request reprint Fondaparinux: use in thromboprophylaxis of acute medical patients
    Sohita Dhillon
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs Aging 25:81-8. 2008
    ..Fondaparinux was generally well tolerated in this clinical trial. In patients receiving fondaparinux, the incidence of major bleeding was similar to that in patients receiving placebo and the incidence of minor bleeding was <3%...
  77. ncbi request reprint Bevacizumab: a review of its use in metastatic colorectal cancer
    Paul L McCormack
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:487-506. 2008
    ..Although cost effectiveness may be a concern, the combination of bevacizumab and fluoropyrimidine-based chemotherapy has potential in the treatment of metastatic colorectal cancer...
  78. doi request reprint Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser
    Sheridan M Hoy
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 69:123-36. 2009
    ..Abdominal pain also occurred less frequently with sodium picosulfate/magnesium citrate than with oral bisacodyl plus a sodium phosphate enema preparation in children and adolescents...
  79. doi request reprint Olmesartan medoxomil: in children and adolescents with hypertension
    Victoria J Muir
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:2439-47. 2010
    ..Oral olmesartan medoxomil was generally well tolerated in children and adolescents with hypertension. The majority of adverse events were of mild to moderate intensity...
  80. ncbi request reprint Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 72:273-300. 2012
    ..In conclusion, tiotropium bromide inhalation powder is a useful option for the maintenance treatment of patients with COPD...
  81. ncbi request reprint Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C
    E B Melian
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:1661-91. 2001
    ..Fever, fatigue, arthralgia, myalgia, headache and rigors were the most frequently reported adverse events. Psychiatric adverse events appeared to be dose-related and caused the majority of treatment withdrawals...
  82. ncbi request reprint Ramelteon
    Adam McGechan
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 19:1057-65; discussion 1066-7. 2005
    ..Adverse events were mostly mild or moderate in nature. Ramelteon has been shown to have no potential for abuse or dependence...
  83. ncbi request reprint Spotlight on topiramate in epilepsy
    Katherine A Lyseng-Williamson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 22:171-4. 2008
    ..Therefore, topiramate is a valuable option as monotherapy or adjunctive therapy in the treatment of epilepsy in adult and paediatric patients...
  84. doi request reprint Torasemide prolonged release
    Katherine A Lyseng-Williamson
    Wolters Kluwer Health, Adis Auckland, New Zealand
    Drugs 69:1363-72. 2009
    ..The PR formulation of torasemide was well tolerated in the clinical trial, with a tolerability profile that was similar to that with the IR formulation...
  85. doi request reprint Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension
    James E Frampton
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 9:309-30. 2009
    ....
  86. doi request reprint Triptorelin embonate (6-month formulation)
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 70:347-53. 2010
    ..Drug-related adverse events (e.g. hot flushes) were consistent with the pharmacological action of triptorelin. Injection-site reactions occurred in 6.7% of triptorelin embonate recipients...
  87. ncbi request reprint Lamivudine. A review of its therapeutic potential in chronic hepatitis B
    B Jarvis
    Adis International Limited, Auckland, New Zealand
    Drugs 58:101-41. 1999
    ..Post-treatment ALT elevations were more common in lamivudine than placebo recipients; however, these generally resolved spontaneously; < or = 1.5% of lamivudine- or placebo-treated patients experienced hepatic decompensation...
  88. ncbi request reprint Tegaserod
    L J Scott
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 58:491-6; discussion 497-8. 1999
    ..No clinically relevant changes in blood pressure, pulse rate, QRS or QTc interval were reported with tegaserod doses of 25 to 100mg...
  89. ncbi request reprint Fibrin sealant: a review of its use in surgery and endoscopy
    C J Dunn
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 58:863-86. 1999
    ....
  90. ncbi request reprint Ropivacaine: an update of its use in regional anaesthesia
    K J McClellan
    Adis International Limited, Auckland, New Zealand
    Drugs 60:1065-93. 2000
    ..The outcome of these inadvertent intravascular administrations was favourable...
  91. ncbi request reprint Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation
    C J Dunn
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 61:1957-2016. 2001
    ....
  92. ncbi request reprint ET-743
    Risto S Cvetkovic
    Adis International Limited, Auckland, New Zealand
    Drugs 62:1185-92; discussion 1193-4. 2002
    ..Transient and reversible elevation of hepatic transaminases, nausea, vomiting and asthenia were common but seldom severe and never treatment-limiting. Mucositis, alopecia and cardiac or neurotoxicities were not observed...
  93. ncbi request reprint Spotlight on the pharmacoeconomics of escitalopram in depression
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:469-73. 2004
    ..In the prospective analysis, escitalopram had lower estimated drug acquisition costs than venlafaxine XR...
  94. ncbi request reprint Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2823-43. 2004
    ..In general, the tolerability profile of peginterferon-alpha-2a plus ribavirin in APRICOT was similar to that previously reported in patients with HCV mono-infection...
  95. ncbi request reprint Naftidrofuryl: a review of its use in the treatment of intermittent claudication
    David R Goldsmith
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 22:967-77. 2005
    ..The magnitude of these effects appears to support claims that the effects of naftidrofuryl are clinically relevant in these patients...
  96. ncbi request reprint Docetaxel: in gastric cancer
    Emma D Deeks
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:1893-901. 2007
    ..general, combination therapy with docetaxel, cisplatin and fluorouracil was relatively well tolerated given the nature of chemotherapy in patients with metastatic or locally advanced/recurrent gastric or gastro-oesophageal adenocarcinoma..
  97. ncbi request reprint Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults
    Emma D Deeks
    Adis, 41 Centorian Drive, Mairangi Bay, Auckland, New Zealand
    BioDrugs 24:287-97. 2010
    ....
  98. doi request reprint Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp
    Paul L McCormack
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:709-30. 2011
    ..Thus, calcipotriol/betamethasone dipropionate is an important, effective, once-daily, topical therapy for the symptomatic treatment of psoriasis vulgaris of the trunk, limbs and scalp...
  99. doi request reprint Ulipristal acetate: a review of its use in emergency contraception
    Kate McKeage
    Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 71:935-45. 2011
    ....
  100. doi request reprint Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy
    Sohita Dhillon
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:1071-91. 2011
    ....
  101. ncbi request reprint Troglitazone: a review of its use in the management of type 2 diabetes mellitus
    G L Plosker
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:409-38. 1999
    ..Among patients who started troglitazone therapy in 1998 (after the incorporation of a boxed warning and increased monitoring requirements in the product labelling), the estimated risk of liver-related death is approximately 1 in 100,000...